



ACROMETA GROUP LIMITED

(Company Registration No.: 201544003M)
(Incorporated in the Republic of Singapore)

**EXTENSION OF EXCLUSIVITY PERIOD UNDER THE NON-BINDING TERM SHEET IN
RESPECT OF THE PROPOSED SALE OF A SUBSIDIARY**

1. INTRODUCTION

The Board of Directors (the “**Board**” or the “**Directors**”) of AcroMeta Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcement dated 13 May 2024 (the “**Previous Announcement**”) in relation to the entry into an indicative non-binding Term Sheet (the “**TS**”) with a global private equity firm (the “**Purchaser**”) in relation to the sale and purchase of all its 70% (the “**Sale Shares**”) of the issued share capital (the “**Proposed Sale**”) of its 70%-owned subsidiary, Life Science Incubator Holdings Pte Ltd (and including its subsidiaries, the “**Target**”) on 11 May 2024.

Unless otherwise defined, all capitalised terms and references used herein shall bear the meanings ascribed to them in the Previous Announcement.

2. EXTENSION OF EXCLUSIVITY PERIOD

The Board wishes to inform that the parties have mutually agreed to extend the Exclusive Negotiating Period to 1 August 2024. All other terms of the TS remain unchanged.

3. FURTHER ANNOUNCEMENTS

The Company will, to the extent necessary, make the relevant disclosures in an announcement in accordance with the requirements of Chapter 9 and Chapter 10 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited including but not limited to the Purchaser details and the consideration. The Company will also make further announcements to update shareholders as appropriate when there are material developments in respect of the Proposed Sale.

4. CAUTION IN TRADING

Shareholders and potential investors should exercise caution when trading in the shares of the Company. The Proposed Sale is subject to, *inter alia*, the execution of definitive agreements and conditions precedent to be fulfilled, and there is no

certainty or assurance that the definitive agreements will be entered into, or that the Proposed Sale will be completed.

The Company will make the necessary announcements when there are further developments on the Proposed Sale and other matters contemplated by this announcement. Shareholders are advised to read this announcement and any further announcements by the Company carefully. Persons who are in doubt as to the actions they should take should consult their legal, financial, tax or other professional advisers.

BY ORDER OF THE BOARD

Lim Say Chin
Executive Chairman and Chief Executive Officer
3 July 2024

*This announcement has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**"), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr Chua Hiang Hwee Jerry, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com